3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Neoplasm Metastasis
7
Lung Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Ovarian Neoplasms
5
Melanoma
5
Carcinoma, Renal Cell
5
Skin Neoplasms
4
Fallopian Tube Neoplasms
4
Carcinoma
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Mouth Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Interventions
pembrolizumab
3
Doxorubicin
3
Standard of Care
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Watchful Waiting
1
Trastuzumab
1
STA 9090
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hemangiosarcoma
×
cemiplimab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled